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Abstract  
Background: The number of studies evaluating the efficacy and safety of third-line 
molecular-targeted therapy for metastatic renal cell carcinoma (mRCC) are limited. 
Methods: The data of 48 patients with disease progression after first-line vascular 
endothelial growth factor receptor tyrosine kinase inhibitor (TKI) and second-line 
targeted therapy, were evaluated. Patients with prior cytokine therapy were excluded. 
Overall survival (OS) after first- and second-line therapy initiation was compared 
according to the use of third-line therapy. In addition, dose-limiting toxicities (DLTs) were 
evaluated.  
Results: Twenty-two of 48 patients (45.8%) received third-line therapy, and TKI and 
mammalian target of rapamycin inhibitor were administered, each, in 11 patients (50%). 
Patients with third-line therapy had significantly longer median OS after first-line (26.6 
vs. 14.6 months, p = 0.0010) and second-line therapy (18.2 vs. 7.4 months, p < 0.0001), 
compared to those without third-line therapy. Multivariable analysis showed that the use 
of third-line therapy following second-line therapy was an independent prognosticator for 
longer OS (hazard ratio: 0.29, 95% confidence interval: 0.14 – 0.58, p = 0.0005). The 
median progression-free survival and OS after third-line therapy was 2.76 and 8.71 
months, respectively. Although a high frequency of DLTs was observed (n = 10, 45.5%), 
the frequencies were similar among the sequential therapies.  
Conclusions: Third-line therapy exhibits a beneficial therapeutic effect in patients with 
mRCC that is resistant to previous therapies. However, there is a need to evaluate in detail 
the high frequency of adverse events, including DLTs.  
 
Key Words 
Third-line targeted therapy for mRCC  Ishihara et al. 
4 
 
renal cell carcinoma; targeted therapy; third-line therapy; tyrosine kinase inhibitor; 
mTORi; metastasis 
  
Third-line targeted therapy for mRCC  Ishihara et al. 
5 
 
Introduction 
Following the discovery of molecular-targeted therapies, the treatment strategies 
for metastatic renal cell carcinoma (mRCC) have been dramatically changed, and patient 
prognosis has improved compared to that in the cytokine therapy era  [1,2]. 
Unfortunately, even after the introduction of targeted therapy, only a limited number of 
patients can achieve complete remission because of the intrinsic or eventual resistance to 
targeted agents [3]. In this context, previous studies have suggested that subsequent 
therapy, including second-, third-line or later, following first-line therapy failure could 
prolong overall survival (OS) [4-6].  
However, after second-line therapy, especially in the third-line setting, clinical 
information regarding the therapeutic efficacy and safety remains limited. In most of the 
previously reported studies, a regular number of patients were treated with cytokine 
therapy [5-10]. However, as the current treatment strategy consists of targeted therapy 
[11], data from patients without a history of cytokine therapy is warranted. Moreover, the 
number of studies reporting the reasons for switching to subsequent therapy (e.g., disease 
progression, not drug intolerability or adverse events [AEs]) is limited. These factors, 
including a history of prior cytokine therapy or reasons for treatment termination, can 
influence the analysis of prognostic outcomes related to sequential therapy in mRCC 
[12,13]. Furthermore, the number of studies evaluating drug tolerability during third-line 
therapy is limited [10].  
Thus, in this study, we investigated the efficacy and tolerability of third-line therapy 
initiated after disease progression in patients with first-line vascular endothelial growth 
factor receptor (VEGFR)-tyrosine kinase inhibitor (TKI) and second-line targeted therapy 
resistant mRCC patients who did not have a prior history of cytokine therapy.  
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Patients and methods 
Study design  
The Internal Ethics Review Board of the Tokyo Women’s Medical University 
approved this retrospective study, which was performed in accordance with the principles 
of the Declaration of Helsinki (ID: 4549). 
In our department, 154 patients had received first-line VEGFR-TKI therapy for 
mRCC without prior cytokine therapy, between January 2007 and June 2017. Detailed 
clinical data were available for the majority of these patients. Among them, 74 patients 
had been switched to second-line therapy after disease progression. Finally, 63 patients 
remained after the exclusion of 11 patients, due to a short second-line therapy duration (n 
= 5) or lack of detailed data (n = 6). Among them, second-line therapy was terminated in 
56 patients. The reasons included disease progression in 52 patients and poor tolerability 
for AEs in 4 patients. Meanwhile, second-line therapy had been continued in 7 patients at 
the time of end of follow-up. Since the aim of this study was to evaluate the impact of 
third-line therapy in sequential targeted therapy, 4 patients receiving immune checkpoint 
inhibitor agents as third-line therapy were excluded. Among the remaining 48 patients 
after disease progression following previous therapies, 22 and 26 patients were classified 
into two groups with and without third-line therapy, respectively. Three patients with a 
short therapy duration (21, 21, and 12 days) were included in the without third-line 
therapy group. The other 23 patients did not receive third-line therapy because of a poor 
general condition mediated by tumor progression (Figure 1). 
Patients receiving hemodialysis therapy or kidney transplantation were excluded 
from the analysis. All clinical and laboratory data were obtained from the electronic 
database and patient medical records. 
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Treatment protocol 
Our protocol for targeted therapy has been described previously [14,15]. Six 
therapeutic agents, including 4 VEGFR-TKIs and 2 mammalian target of rapamycin 
inhibitors (mTORis) were selected based on the insurance coverage guidelines followed 
in Japan. Based on the current consensus guidelines, the main agent for first-line targeted 
therapy in our protocol was sunitinib. Axitinib has been included under insurance 
coverage as second-line or later therapy in Japan. Therefore, we selected axitinib as an 
agent for second-line therapy. For third-line therapy, we did not have a definitive protocol. 
TKI and mTORi were preferably chosen as third-line agents after second-line mTORi and 
TKI failure, respectively. When a durable response was achieved with both first- and 
second-line TKIs, another TKI could be selected as third-line therapy. Meanwhile, in 
patients with a history of treatment refractory (i.e., non-efficacy) or intolerability, agents 
with the same mechanism of action could be avoided. 
Post-treatment follow-up scans, using computed tomography or magnetic 
resonance imaging of the chest, abdomen, and pelvis, were obtained at regular 4 to 12 
week intervals depending on the patient’s condition. 
Drugs were administered until disease progression or intolerable AEs were 
observed.  
 
Objective response on targeted therapy 
Target lesions were selected based on the results of baseline imaging and evaluated 
according to the standard Response Evaluation Criteria in Solid Tumors (RECIST) 
version 1.1.  
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Adverse events on targeted therapy 
AEs were assessed according to the Common Terminology Criteria for Adverse 
Events of the National Cancer Institute (CTCAE), version 4.0, and subsequently, dose 
modifications, including reduction or interruption (i.e., dose-limiting toxicities [DLTs]), 
were performed as necessary.   
 
Statistical analysis  
Continuous variables were analyzed using the Mann-Whitney U test, and 
categorical variables were analyzed using the χ2 test or Fisher’s extract test. Time to 
progression (TTP) and progression-free survival (PFS) were defined as the time from 
therapy initiation to the date of progression. OS was defined as the time from therapy 
initiation to the date of death from any cause. Survival was calculated using the Kaplan-
Meier method and compared using the log-rank test. Univariable and multivariable 
analyses using Cox proportional hazards regression models were used to identify 
prognosticators for survival. Survival risk was expressed as the hazard ratios (HRs) and 
95% confidence intervals (CIs). All statistical analyses were conducted using JMP 
software (version 11; SAS Institute Inc., Cary, NC, USA), and p < 0.05 was considered 
statistically significant. 
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Results  
Patients’ background 
Table 1 shows details of the patients’ background. The Memorial Sloan Kettering 
Cancer Center (MSKCC) risk in second- and third-line therapy, was based on Motzer’s 
classification [16]. Patients with third-line therapy had a significantly longer duration of 
median second-line TTP (7.06 vs. 3.29 months, p = 0.0005), compared to those without 
third-line therapy. There were no significant differences in other clinicopathological 
factors, including age, sex, MSKCC risk, pathological type, nephrectomy status, 
metastatic status, and previous therapy regimens (all, p > 0.05). The median follow-up 
period was significantly shorter in patients without third-line therapy, compared to those 
with third-line therapy (13.7 vs. 25.9 months, p = 0.0003). 
 
Therapeutic effect of third-line therapy 
During the follow-up period, 39 of 48 patients (81.3%) died of any cause after 
termination of second-line therapy. Figure 2 shows that patients with third-line therapy 
had significantly longer median OS after first-line (26.6 [95% CI: 20.3 – 63.1] vs. 14.6 
[95% CI: 11.3 – 20.1] months, p = 0.0010) and second-line therapy (18.2 [95% CI: 11.1 
– 38.7] vs. 7.4 [95% CI: 4.9 – 9.8] months, p < 0.0001), compared to those without third-
line therapy. Table 2 shows the results of univariable and multivariable analyses for OS 
after second-line therapy. Univariable analysis showed that second-line MSKCC risk (p 
= 0.0084), number of metastases at second-line therapy initiation (p = 0.0066), and the 
use of third-line therapy (p = 0.0001) were associated with survival. Multivariable 
analysis showed that the use of third-line therapy was an independent prognosticator (HR: 
0.29, 95% CI: 0.14 – 0.58, p = 0.0005), together with second-line MSKCC risk (HR: 2.76, 
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95% CI: 1.31 – 5.64, p = 0.0086). 
Histological type had a significant influence on treatment strategy and outcome 
[17,18]. Thus, after the exclusion of 14 patients with a diagnosis of non-clear-cell 
carcinoma (CCC), we analyzed OS after first- and second-line therapy. Consequently, 
third-line therapy was performed in 16 of 34 (47.1%) patients with CCC, and the median 
OS after first- and second-line therapy were significantly longer in patients with third-
line therapy, compared to those without third-line therapy (after first-line: 30.6 [95% CI: 
19.1 – 81.2] vs. 18.5 [95% CI: 12.8 – 27.0] months, p = 0.0010; after second-line: 21.8 
[95% CI: 19.1 – 81.2] vs. 8.34 [95% CI: 12.8 – 27.0] months, p = 0.0013) (Supplementary 
Figure 1).  
 
Patient prognosis after third-line therapy 
During the follow-up period after third-line therapy, 20 of 22 patients (90.9%) 
experienced disease progression and 16 of 22 patients (72.7%) died from any cause. TKI 
and mTORi were administered as third-line agents, each, in 11 patients (50.0%). The 
sequential therapeutic regimens consisted of TKI-TKI-mTORi (n = 11, 50.0%), TKI-
mTORI-TKI (n = 6, 27.3%), and TKI-TKI-TKI (n = 5, 22.7%), respectively (Table 1). 
The objective response rate of the third-line therapy agents was determined for individual 
patients by a waterfall plot analysis, as shown in Supplementary Figure 2. Figure 3 shows 
that the median PFS and OS after third-line therapy was 2.76 (95% CI: 1.94 – 7.79) and 
8.71 (95% CI: 4.6 – 31.0) months, respectively. Moreover, in the 16 patients with a 
diagnosis of CCC, the median PFS and OS after third-line therapy was 3.22 (95% CI: 
1.94 – 8.28), and 11.0 (95% CI: 4.08 – 31.0) months, respectively.   
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Objective response rate during sequential therapy 
Figure 4 shows the objective response rates during sequential therapy. During first-
line therapy, partial response, stable disease, and progressive disease were observed in 6 
(27.3%), 12 (54.5%), and 4 (18.2%) patients, respectively. Likewise, during second- and 
third-line therapy, partial response, stable disease, and progressive disease were observed 
in 4 (18.2%), 16 (72.7%), and 2 (9.09%), and 4 (18.2%), 7 (31.8%), and 11 (50.0%) 
patients, respectively. The magnitude of best tumor shrinkage was lower with third-line 
therapy, compared to that with previous therapies, whereas the proportion of patients who 
experienced partial response was similar among the sequential therapy regimens.   
 
Dose-limiting toxicity during sequential therapy 
As shown in Table 3, 10 of 22 patients (45.5%) experienced DLTs for AEs of grade 
2 (n = 9, 40.9%) and ≥ 3 (n = 7, 31.8%) in third-line therapy. Similar frequencies of DLTs 
were observed between sequential therapy regimens (first-line: 45.5%; second-line: 
59.1%). Moreover, the component rates of treatment modifications (i.e., reduction vs. 
interruption) were similar (reduction: 36.4%, 27.3%, and 22.7% in first-, second-, and 
third-line therapy).  
  
Third-line targeted therapy for mRCC  Ishihara et al. 
12 
 
Discussion 
In this study, we demonstrated that third-line targeted therapy after first-line 
VEGFR-TKI and second-line therapy for mRCC had a beneficial therapeutic effect in 
patients without previous cytokine therapy and with disease progression after prior 
therapies. In addition, although patients had a high risk for developing AEs, including 
DLTs, the frequency was similar among the sequential therapy regimens. 
Although the therapeutic effect of sequential therapy has been recognized [4,5], 
only a limited patient population can switch to the subsequent therapy. It has previously 
been reported that only a maximum of 13.0% – 21.0% of patients could receive third-line 
therapy [5,6,19,20]. In this study, 14.3% of patients (n = 22) subsequently underwent 
third-line therapy. This finding was consistent with those of previous reports. The median 
OS (from the time of commencing first-line therapy) was shorter than that reported in 
previous studies; we found that the median OS after first-line therapy was 26.6 months in 
patients receiving third-line therapy, whereas Ko et al. and Busch et al. have reported a 
median OS of 39.2 and 35.6 months, respectively [6,10]. In the present study, the median 
PFS and OS after third-line therapy was 2.76 and 8.71 months, respectively. Wells et al. 
have reported that the median PFS and OS were 3.9 and 12.4 months [5], respectively, 
and Busch et al. have reported a median PFS of 3.7 months [10]. Thus, OS, rather than 
PFS, had a trend towards being shorter in our study. Although it is difficult to explain 
these differences, two unique features of this study might be considered. First, Escudier 
et al. have suggested that patients treated with cytokine therapy for a long period of time 
may have developed an inherently less-aggressive disease or a better general condition, 
resulting in patient bias [12]. According to Wells et al., the median OS (from the time of 
cessation of second-line therapy) was 7.6 months in patients without third-line therapy 
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[5]. Moreover, De Velasco et al. have reported that patients whose reason for therapy 
withdrawal was intolerability had a superior prognosis after the subsequent therapy, 
compared to those with disease progression [13]. Thus, it is not surprising that a poorer 
outcome was observed in the present study as the cohort of this study consisted of patients 
without a prior history of cytokine therapy and whose reasons for switching to the next 
therapy was disease progression. 
In our analysis, the proportion of patients with a diagnosis of non-CCC was lower 
in those with third-line therapy, compared to those without third-line therapy. The 
pathological difference may influence prognosis because the oncological outcome is 
supposed to differ between CCC and non-CCC populations [18]. Nevertheless, after the 
exclusion of pathological influence, the therapeutic effect of third-line therapy was 
confirmed. 
In the present study, the objective response rate was also poorer during third-line 
therapy. Notably, half of the patients had progressive disease as the best response to third-
line therapy. Therefore, for such resistance of tumors to targeted therapies, a change in 
approach might be needed, such as introducing an antibody inhibitor (nivolumab) of the 
programmed death 1 immune checkpoint protein [3,21]. Meanwhile, there were no 
differences in partial response rates during sequential therapy. Thus, a proportion of 
patients achieved a good response, even to third-line therapy. Indeed, these patients had 
a favorable prognosis after third-line therapy (median third-line PFS: 22.3 months, OS: 
31.6 months). 
Approximately half of the patients experienced DLTs during third-line therapy 
(45.5%). Frequencies were similar among the sequential therapies. Busch et al. have 
reported similar frequencies of AEs between first/second-line and third-line therapy [10]. 
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Furthermore, according to Buchler et al., the incidence of serious toxicities (grades ≥3) 
was similar between second- and third-line everolimus therapy [8]. Meanwhile, Oudard 
et al. have indicated that the rate of development of AEs was higher in patients with third-
line or later sunitinib rechallenge therapy, compared to those with first-line sunitinib 
therapy, even though the initial dose was reduced or the treatment schedule was made 
easier in subsequent therapies [7]. Although in this study, neither the grade nor the types 
of AEs varied among sequential therapies, hematotoxicity was frequently observed in 
first-line therapy due to TKI usage. 
This study has several limitations. First, this was a retrospective study performed 
in a single center with a relatively small sample size. Thus, patients with a poor 
performance status or other patient-related backgrounds could influence the physician’s 
treatment plan. Therefore, unmeasured or immeasurable confounders could have affected 
our results. Moreover, we could not analyze the superiority among regimens (i.e., TKI-
TKI-mTORi vs. TKI-mTORi-TKI) due to the inherent nature of a retrospective 
observational study. Indeed, as shown in Supplementary Figure 2, mTORi had a lower 
objective response rate than TKI. Other clinicopathological factors were not associated 
with objective response rate (data not shown). Moreover, patients with TKI-TKI-mTORi 
had a shorter third-line PFS and OS, compared to those with other regimens (data not 
shown). Therefore, these findings should be confirmed in future prospective randomized 
clinical trials. Second, even though present-day guidelines do not recommend sorafenib 
as a preferential first-line agent, patients receiving sorafenib as first-line therapy were 
included in this study, because neither sunitinib nor pazopanib was approved in Japan 
during the observational period (2007 onwards). Third, due to the heterogeneity of the 
sequential therapy regimens, we could not calculate the relative dose intensity, an 
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important factor for evaluating the prognosis and tolerability. 
In conclusion, this study showed that third-line targeted therapy had a beneficial 
therapeutic effect in patients with first-line VEGFR-TKI and second-line resistant mRCC, 
who do not have a prior history of cytokine therapy. Moreover, similar levels of 
tolerability were observed in third-line therapy, compared to those in previous therapies. 
However, there is a need to evaluate, in detail, the high frequency of AEs, including DLTs.  
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Figure legends 
Figure 1. 
Study design 
Patients receiving hemodialysis therapy or kidney transplantation were excluded. 
None of the patients had undergone prior cytokine therapy. Three patients receiving 
immune checkpoint inhibitor therapy, programmed cell death 1 (nivolumab), as third-line 
therapy were excluded, whereas three patients receiving more than four lines of therapy 
were included in the analysis. Three patients with short therapy durations were 
categorized into the without third-line therapy group. 
VEGFR, vascular endothelial growth factor receptor; TKI, tyrosine kinase inhibitor 
 
Figure 2.  
Overall survival after first- and second-line therapy according to the use of third-
line therapy 
Patients with third-line therapy (n = 22) had a significantly longer overall survival 
after first- and second-line therapy as compared to those without third-line therapy. (a) 
Median overall survival after first-line therapy: 26.6 vs. 14.6 months, p = 0.0010. (b) 
Median overall survival after second-line therapy: 18.2 vs. 7.4 months, p < 0.0001. 
CI, confidence interval 
 
Figure 3. 
Progression-free and overall survival after third-line therapy 
The Kaplan-Meier survival curve method shows that the median progression-free 
and overall survival after third-line therapy was 2.76 and 8.71 months, respectively. (a) 
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progression-free survival. (b) overall survival.  
 
Figure 4. 
Objective response rates during sequential therapy 
Objective response rates were lower with third-line therapy, compared to that with 
previous therapies, whereas the proportion of patients who experienced partial response 
was similar among the sequential therapy regimens. 
PR, partial response; SD, stable disease; PD, progression disease 
 
Supplementary materials 
Supplementary Figure 1. 
Overall survival after first- and second-line therapy according to the use of third-
line therapy in 34 patients with a diagnosis of clear-cell carcinoma 
Patients with third-line therapy (n = 16) had a significantly longer overall survival 
after first- and second-line therapy as compared to those without third-line therapy. (a) 
Median overall survival after first-line therapy: 30.6 vs. 18.5 months, p = 0.0110. (b) 
Median overall survival after second-line therapy: 21.8 vs. 8.34 months, p = 0.0013.   
 
Supplementary Figure 2. 
Waterfall plot analysis 
Waterfall plot analysis shows the objective response rate according to the third-line 
agents used in each patient.  
mTORi, mammalian target of rapamycin inhibitor 
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Table 1. Patients’ background 
Variable  All  
(n = 48) 
With third-line therapy 
(n = 22) 
Without third-line therapy 
(n = 26) 
p  
Age at therapy initiation, years-old* 
 First-line 
 Second-line 
 Third-line 
 
64.5 (56.0 – 73.5) 
65.5 (57.5 – 73.5) 
64.5 (54.8 – 72.3) 
 
63.5 (51.5 – 70.3) 
63.5 (52.8 – 70.5) 
64.5 (54.8 – 72.3) 
 
67.0 (61.5 – 74.0) 
68.5 (61.5 – 74.0) 
NA 
 
0.203 
0.165 
NA 
Sex  
 Male (ref. female) 
 
32 (66.7%) 
 
15 (68.2%) 
 
17 (65.4%) 
 
0.838 
First-line MSKCC 
 Favorable/intermediate/poor 
Second-line MSKCC** 
 Favorable/intermediate/poor 
Third-line MSKCC** 
 Favorable/intermediate/poor 
 
5 (10.4%)/ 38 (79.2%)/ 5 (10.42%) 
 
2 (4.17%)/ 31 (64.6%)/ 15 (31.3%) 
 
NA 
 
1 (4.55%)/ 19 (86.4%)/ 2 (9.09%) 
 
0/ 17 (77.3%)/ 5 (22.7%) 
 
1 (4.55%)/ 14 (63.6%)/ 7 (31.8%) 
 
4 (15.4%)/ 19 (73.1%)/ 3 (11.5%) 
 
2 (7.69%)/ 14 (53.9%)/ 10 (38.5%) 
 
NA 
 
0.782 
 
0.241 
 
NA 
Pathology  
 Clear-cell carcinoma 
 Clear-cell carcinoma with spindle 
 Papillary renal cell carcinoma  
 Other/unknown    
 
34 (70.8%) 
4 (8.33%) 
5 (10.4%) 
5 (10.4%) 
 
16 (72.7%) 
1 (4.55%) 
1 (4.55%) 
4 (18.2%) 
 
18 (69.2%) 
3 (11.5%) 
4 (15.4%) 
1 (3.85%) 
0.791 
Prior nephrectomy   
 With (ref. without) 
 
44 (91.7%) 
 
20 (90.9%) 
 
24 (92.3%) 
 
0.861 
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Number of metastatic sites at first-line therapy initiation 
 Multiple (ref. single) 
Number of metastatic sites at second-line therapy initiation 
 Multiple (single) 
Number of metastatic sites at third-line therapy initiation 
 Multiple (single) 
 
26 (54.2%) 
 
34 (70.8%) 
 
NA 
 
10 (45.5%) 
 
13 (59.1%) 
 
16 (72.7%) 
 
16 (61.5%) 
 
21 (80.8%) 
 
NA 
 
0.265 
 
0.0997 
 
NA 
First-line TKI agent  
  Sorafenib/sunitinib/pazopanib 
Second-line molecular-targeted agent 
 TKI 
  Sorafenib/sunitinib/pazopanib/axitinib 
 mTORi 
  Temsirolimus/everolimus 
Third-line molecular-targeted agent 
 TKI 
  Sorafenib/sunitinib/pazopanib/axitinib 
 mTORi 
  Temsirolimus/everolimus 
 
14 (29.2%)/ 32 (66.7%)/ 2 (4.17%) 
 
37 (77.1%) 
2 (4.17%)/10 (20.8%)/ 3 (6.25%)/ 22 (45.8%) 
11 (22.9%) 
3 (6.25%)/ 8 (16.7%) 
 
NA 
 
4 (18.2%)/ 17 (77.3%)/ 1 (4.55%) 
 
16 (72.7%) 
2 (9.09%)/ 3 (13.6%)/ 2 (9.09%)/ 9 (40.9%) 
6 (27.3%) 
2 (9.09%)/ 4 (18.2%) 
 
11 (50.0%) 
2 (9.09%)/ 2 (9.09%)/ 0/ 7 (31.8%) 
11 (50.0%) 
2 (9.09%)/ 9 (40.9%)  
 
10 (38.5%)/ 15 (57.7%)/ 1 (3.85%) 
 
21 (80.8%) 
0/ 7 (26.9%)/ 1 (3.85%)/ 13 (50.0%) 
5 (19.2%) 
1 (3.85%)/ 4 (15.4%) 
 
NA 
 
0.304 
 
0.509 
 
 
 
 
NA 
Regimen of therapy 
 TKI-TKI 
 TKI-mTORi 
 TKI-TKI-TKI 
 TKI-TKI-mTORi 
 
37 (77.1%) 
11 (22.9%) 
NA 
NA 
 
16 (72.7%) 
6 (27.3%) 
5 (22.7%) 
11 (50.0%) 
 
21 (80.8%) 
5 (19.2%) 
NA 
NA 
 
0.509 
NA 
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 TKI-mTORi-TKI NA 6 (27.3%) NA 
Time to progression, months*  
 First-line 
 Second-line 
 
7.91 (5.22 – 11.6) 
5.50 (3.00 – 8.16) 
 
8.94 (5.18 – 11.5) 
7.06 (5.24 – 12.4) 
 
6.66 (5.19 – 11.8) 
3.29 (2.3 – 6.20) 
 
0.555 
0.0005 
Follow-up period, months* 20.2 (12.8 – 34.9) 25.9 (20.0 – 58.2) 13.7 (10.0 – 25.6) 0.0003 
*Median (interquartile range) 
**Second- and third-line MSKCC risk was defined according to Motzer’s risk classification. 
ref, reference; MSKCC, Memorial Sloan Kettering Cancer Center; TKI, tyrosine kinase inhibitor; mTORi, mammalian target of rapamycin, NA; not applicable  
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Table 2. Univariable and multivariable analyses for prognosticators for overall survival after second-line therapy 
Variable  Univariable 
HR (95%CI) 
p value Multivariable 
HR (95%CI) 
p  
Age at therapy initiation (continuous variable) 
 First-line 
 Second-line 
 
0.99 (0.96 – 1.02) 
0.99 (0.96 – 1.01) 
 
0.373 
0.315 
  
Sex  
 Male (ref. female) 
 
0.79 (0.42 – 1.57) 
 
0.495 
  
First-line MSKCC 
 Poor (ref. favorable and intermediate) 
Second-line MSKCC 
 Poor (ref. favorable and intermediate) 
 
1.55 (0.46 – 3.97) 
 
2.72 (1.31 – 5.45) 
 
0.437 
 
0.0084 
 
 
 
2.76 (1.31 – 5.64) 
 
 
 
0.0086 
Pathology  
 Clear-cell carcinoma (ref. non-clear-cell carcinoma) 
 
0.63 (0.32 – 1.39) 
 
0.240 
  
Prior nephrectomy   
 With (without) 
 
0.93 (0.28 – 5.74) 
 
0.918 
  
Number of metastatic sites at first-line initiation 
 Multiple (ref. single) 
Number of metastatic sites at second-line initiation 
 Multiple (ref. single) 
 
2.24 (1.16 – 4.51) 
 
2.80 (1.31 – 6.70) 
 
0.0168 
 
0.0066 
 
 
 
1.67 (0.76 – 4.12) 
 
 
 
0.207 
Regimen of therapy 
 TKI-TKI (ref. TKI-mTORi) 
 
1.66 (0.79 – 3.92) 
 
0.190 
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Time to progression (continuous variable) 
 First-line 
 
0.97 (0.92 – 1.01) 
 
0.180 
  
Third-line therapy 
 With (ref. without) 
 
0.27 (0.13 – 0.53) 
 
0.0001 
 
0.29 (0.14 – 0.58) 
 
0.0005 
HR, hazard ratio; CI, confidence interval 
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Table 3. Dose-limiting toxicity and adverse events during sequential therapy  
First-line therapy Second-line therapy Third-line therapy 
Dose-limiting toxicity 
 With  
 
10 (45.5%) 
 
13 (59.1%) 
 
10 (45.5%) 
Components of modification  
 Reduction 
 Interruption 
 
8 (36.4%) 
4 (18.2%) 
 
6 (27.3%) 
7 (31.8%) 
 
5 (22.7%) 
6 (27.3%) 
Reasons for dose-limiting toxicity 
 Stomatitis  
 Interstitial lung disease 
 Anemia 
 Diarrhea   
 Nausea/ vomiting 
 Hand foot syndrome 
 Fatigue  
 Anorexia 
 Pneumonia 
 Weight loss 
 Thrombocytopenia  
 Gastrointestinal bleeding 
 Kidney dysfunction  
 Liver dysfunction  
 Back pain 
 
0 
0 
0 
0 
0 
3 (13.6%) 
2 (9.09%) 
0 
0 
0 
3 (13.6%) 
0 
0 
0 
0 
 
1 (4.55%) 
1 (4.55%) 
1 (4.55%) 
0 
2 (9.09%) 
1 (4.55%) 
2 (9.09%) 
1 (4.55%) 
0 
1 (4.55%) 
2 (9.09%) 
1 (4.55%) 
2 (9.09%) 
1 (4.55%) 
1 (4.55%) 
 
1 (4.55%) 
1 (4.55%) 
2 (9.09%) 
3 (13.6%) 
1 (4.55%) 
1 (4.55%) 
1 (4.55%) 
1 (4.55%) 
1 (4.55%) 
1 (4.55%) 
1 (4.55%) 
0 
0 
0 
0 
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 Leukocytopenia    3 (13.6%) 0 0 
Grades for adverse events inducing dose-limiting toxicity 
Grade 2 
Grade ≥ 3 
 
7 (31.8%) 
5 (22.7%) 
 
6 (27.3%) 
10 (45.5%) 
 
9 (40.9%) 
7 (31.8%) 
 
74 patients receiving second-line molecular-targeted therapy
Disease 
progression in 52 
patients
Therapy 
continuation in 7 
patients
22 patients shifting 
to third-line therapy
26 patients without 
third-line therapy
4 patients with immune checkpoint 
inhibitor therapy as third-line therapy 
were excluded
11 patients were excluded as follows:
• Short therapy duration (n = 5)
• Missing clinical data (n = 6)
Intolerability in 4 
patients
154 patients receiving first-line VEGFR-TKI therapy
63 patients
48 patients
Mainly evaluated in this study
Figure 1
With        26.6 months (95% CI: 20.3 – 63.1)
Without    14.6 months (95%CI: 11.3 – 20.1)
p = 0.0010
Without
With With
Without
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Figure 2
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p < 0.0001
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